Abstract:Background: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied. Methods: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells' ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo. Results: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice. Conclusions: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment.

Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors

Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer

Cancer Research Advance in CKLF-like MARVEL Transmembrane Domain Containing Member Family (Review).

CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value

Chemokine-Like Factor-Like Marvel Transmembrane Domain-Containing Family In Hepatocellular Carcinoma: Latest Advances

Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma

Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 As a Novel Biomarker for Breast Cancer.

Research advances in CKLF-like MARVEL transmembrane domain containing member 5]

Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.

Chemokine-like Factor-Like MARVEL Transmembrane Domain-Containing Family in Autoimmune Diseases

Research Advances in Chemokine-like Factor Super Family Member 8

CMTM6, a potential immunotherapy target

The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment

CMTM3 As a Potential New Immune Checkpoint Regulator

Regulative Role of the CXCL13-CXCR5 Axis in the Tumor Microenvironment

Chemokines and their role in tumor growth and metastasis

CMTM4 is Frequently Downregulated and Functions As a Tumour Suppressor in Clear Cell Renal Cell Carcinoma

CMTM1_v17 is a novel potential therapeutic target in breast cancer.

The Role of Cxc Chemokines and Their Receptors in the Progression and Treatment of Tumors

Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer

Research Advances in the Role of the Tropomyosin Family in Cancer